Nevro Corp. (NVRO) News
Filter NVRO News Items
NVRO News Results
|Loading, please wait...|
NVRO News Highlights
- NVRO's 30 day story count now stands at 11.
- Over the past 24 days, the trend for NVRO's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about NVRO are SCS, DECK and HOLX.
Latest NVRO News From Around the Web
Below are the latest news stories about Nevro Corp that investors may wish to consider to help them evaluate NVRO as an investment opportunity.
The following slide deck was published by Nevro Corp. in conjunction with their 2021 Q4 earnings call....
Nevro Corp. (NVRO) Q4 2021 Earnings Conference Call February 23, 2022 4:30 P.M. ET Company Participants Julie Dewey - Corporate Communications and Investor Relations Officer Keith Grossman - Chairman, Chief Executive Officer and President Rod MacLeod - Chief Financial Officer Conference Call Participants Chris Pasquale - Guggenheim Adam Maeder -...
Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q4 due to soft geographical performances.
Nevro (NVRO) delivered earnings and revenue surprises of 0% and 0.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Nevro Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides First Quarter and Full-Year 2022 Guidance
Nevro Corp. (NYSE: NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for the fourth quarter and full-year ended December 31, 2021 and provided guidance for the first quarter and full-year of 2022.
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, Rod MacLeod, Chief Financial Officer, and Dr. David Caraway, Chief Medical Officer, will participate in the Wells Fargo 2022 MedTech R&D Spotlight Call Series on Friday, March 4, 2022 at 10:00 am Eastern Time.
Nevro Announces Publication of 12-Month Data from SENZA-NSRBP Randomized Controlled Trial in Journal of Neurosurgery: Spine
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced 12-month data from the SENZA-NSRBP randomized controlled trial (RCT) was published online in Journal of Neurosurgery: Spine.1 These data show that high-frequency 10 kHz spinal cord stimulation (SCS) therapy results in profound improvement in non-surgical refractory back pain (NSRBP) patients compared to Conventional Medical Managem
The offering, set to close Tuesday, comes less than a year after the company raised a whopping $115 million in Series C funding.
Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.
Hologic (HOLX) delivered earnings and revenue surprises of 80.83% and 31.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?